2-PA Stats & Data

Identity warning: Reports indicate some vendors use the name “2-PA” for the parent cathinone (2‑amino‑1‑phenyl‑1‑propanone), while others confuse it with 2‑phenylacetamide (a different, non-stimulant amide); verify with reagent or laboratory testing before dosing. Cathinone itself is scheduled in multiple jurisdictions (e.g., US Schedule I), so materials that actually are the parent cathinone carry significant legal risk. Assume typical cathinone stimulant risks: tachycardia, hypertension, vasoconstriction, hyperthermia, anxiety, insomnia, and a strong urge to redose—avoid consecutive-day or continuous use. For oral use, wait at least 2 hours before considering any redose to avoid stacking. Hydrate with electrolytes (not only water) and take cooling breaks in hot or crowded settings to reduce hyperthermia risk; do not overhydrate due to hyponatremia risk. Insufflation commonly causes marked nasal irritation; mitigate by using fine powders, alternating nostrils, and rinsing with sterile saline after sessions; avoid oxymetazoline longer than 3 days due to rebound congestion. Avoid combining with MAOIs (including harmala alkaloids) due to hypertensive crisis risk, and avoid combining with bupropion or tramadol because of additive seizure risk. Stimulant markets frequently show mislabeling/adulteration (e.g., samples sold as one cathinone containing different cathinones or, in stimulant markets, unexpected benzodiazepines/nitazenes), so drug checking is strongly recommended before use. People with cardiovascular disease, hypertension, glaucoma, hyperthyroidism, or a history of seizures should avoid use; seek medical evaluation if chest pain, severe headache, hyperthermia, confusion, or persistent agitation occur.